Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A Phase III Randomized Study Comparing Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in Patients with Advanced Ovarian Cancer

D. MOURATIDOU, C. GENNATAS, V. MICHALAKI, A. PAPADIMITRIOU, CH. ANDREADIS, C. SYKIOTIS and N. TSAVARIS
Anticancer Research January 2007, 27 (1B) 681-685;
D. MOURATIDOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. GENNATAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gennatas@otenet.gr
V. MICHALAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. PAPADIMITRIOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CH. ANDREADIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. SYKIOTIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. TSAVARIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To assess progression-free survival (PFS) and overall survival (OS) in patients with advanced epithelial ovarian cancer receiving the combination of cisplatin (75 mg/m2 i.v.) and cyclophosphamide (700 mg/m2 i.v.) (CP), or the combination of paclitaxel (175 mg/m2) followed by cisplatin (75 mg/m2) (TP). Patients and Methods: One hundred and twenty patients were randomized to receive six cycles of one of the treatments every 3 weeks. If measurable, complete response (CR) or partial response (PR) was determined. Results: There was a significant difference (p<0.05) in the frequency of response (CR+PR) rates between treatment groups, in favor of paclitaxel containing regimen. The median PFS was 9 months for patients in the CP group and 12 months for patients in the TP group (log-rank p=0.215). The median OS were 24 months and 20 months in TP and CP arms, respectively (log-rank p=0.350). Neutropenia and alopecia were more severe with paclitaxel-containing regimen. Conclusion: Although OS and PFS were similar in two arms, TP regimen yielded superior response rates relative to CP, with an acceptable toxicity profile. Therefore, the TP regimen remains the preferred initial treatment option.

  • Cyclophosphamide
  • paclitaxel
  • ovarian cancer

Footnotes

  • Received June 26, 2006.
  • Revision received December 4, 2006.
  • Accepted December 5, 2006.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (1B)
Anticancer Research
Vol. 27, Issue 1B
January-February 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase III Randomized Study Comparing Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in Patients with Advanced Ovarian Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Phase III Randomized Study Comparing Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in Patients with Advanced Ovarian Cancer
D. MOURATIDOU, C. GENNATAS, V. MICHALAKI, A. PAPADIMITRIOU, CH. ANDREADIS, C. SYKIOTIS, N. TSAVARIS
Anticancer Research Jan 2007, 27 (1B) 681-685;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Phase III Randomized Study Comparing Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in Patients with Advanced Ovarian Cancer
D. MOURATIDOU, C. GENNATAS, V. MICHALAKI, A. PAPADIMITRIOU, CH. ANDREADIS, C. SYKIOTIS, N. TSAVARIS
Anticancer Research Jan 2007, 27 (1B) 681-685;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve
  • Google Scholar

More in this TOC Section

  • Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma
  • Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver
  • Pancreaticoenterostomy With Seromuscular-parenchymal Anastomosis for Prevention of Postoperative Pancreatic Fistula in Distal Pancreatectomy
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire